A novel MGB probe-based assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPMI (nucleophosmin) exon 12 mutations
| Authors | |
|---|---|
| Year of publication | 2008 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Insertions into exon 12 of NPM1 gene represent the most frequent molecular aberration in the subgroup of patients with AML otherwise showing normal karyotype. Therefore, NPM1 mutations may be used as a marker for quantification of minimal residual disease (MRD). Here we propose highly sensitive and reproducible MGB probe-based method for MRD. |
| Related projects: |